Cite
HARVARD Citation
Palandri, F. et al. (2020). Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 126 (6), pp. 1243-1252. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Palandri, F. et al. (2020). Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 126 (6), pp. 1243-1252. [Online].